Eurand Announces First Quarter 2008 Financial Results Conference Call

Corporate news announcement processed and transmitted by Hugin ASA. The issuer is solely responsible for the content of this announcement. ---------------------------------------------------------------------- -------------- AMSTERDAM, Netherlands, April 17, 2008 (PRIME NEWSWIRE) -- Eurand N.V. (Nasdaq:EURX), a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies, will host a conference call on Friday, May 9, 2008 at 8:30 AM ET to report its first quarter 2008 financial results. The conference call will be hosted by Gearoid Faherty, Chief Executive Officer, and Mario Crovetto, Chief Financial Officer. Conference call schedule: 8:00 AM ET: First quarter 2008 financial results will be released 8:20 AM ET: To participate in the conference call: -- U.S. Participants dial 1-877-407-0789 -- International Participants dial +1-201-689-8562 8:30 AM ET: Conference call begins promptly Call Replay: A dial-up replay of the call will be available until June 9, 2008. The Account Number is is: 3055, Conference ID Number: 282168. -- U.S. Participants dial 1-877-660-6853 -- International Participants dial +1-1-201-612-7415 A live web cast of the call will also be available from the Investor Relations section on the corporate web site at Following the live webcast, the archived version of the call will be available at the same URL until June 9, 2008. About Eurand Eurand is a specialty pharmaceutical company that develops, manufactures and commercializes enhanced pharmaceutical and biopharmaceutical products based on its proprietary drug formulation technologies. Eurand has had four partnered products approved by the FDA since 2001 and has a pipeline of product candidates in development for itself and its collaboration partners. Eurand has completed two phase III clinical trials on its lead product candidate, Zentase(tm) (EUR-1008), intended for the treatment of Exocrine Pancreatic Insufficiency and has submitted an NDA for this product which has been granted priority review. Eurand's technology platforms include bioavailability enhancement of poorly soluble drugs, customized release, taste-masking/fast-dissolving formulations and drug conjugation. Eurand is a global company with facilities in the USA and Europe. For more information, visit Eurand's website at This release, and oral statements made with respect to information contained in this release, constitutes forward-looking statements. Such forward-looking statements include those which express plan, anticipation, intent, contingency, goals, targets or future development and/or otherwise are not statements of historical fact including, but not limited to our plans for our NDA filing, enrollment and future plans for our clinical trials, progress of and reports of results from clinical studies, clinical development plans and product development activities. The words "potentially", "could", "calls for" and similar expressions also identify forward-looking statements. These statements are based upon management's current expectations and are subject to risks and uncertainties, known and unknown, which could cause actual results and developments to differ materially from those expressed or implied in such statements. Factors that could affect actual results include risks associated with the possibility that the FDA refuses to approve our NDA; the outcome of any discussions with the FDA; and unexpected delays in preparation of materials for submission to the FDA as a part of our NDA filing. Forward-looking statements contained in this press release are made as of this date, and we undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future events or otherwise. Actual events could differ materially from those anticipated in the forward-looking statements. CONTACT: Eurand N.V. Mario Crovetto, Chief Financial Officer +39 02 95428 521 The Ruth Group Nick Laudico 646-536-7030 Elizabeth Scott 646-536-7014 --- End of Message --- Eurand N.V. 845 Center Drive Vandalia, Ohio USA WKN: A0MSPK; ISIN: NL0000886448; ;